Stavros G. Vizirgianakis insider trades: Xtant Medical Holdings (XTNT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stavros reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 7, 2022 | XTNT | ↑ Buy | 2,264,861 | $0.48 | $1.1M | Direct | Oct 11, 2022 (4d) |
| Mar 12, 2020 | MSON | ↑ Buy | 10,000 | $9.84 | $98K | Direct | Mar 12, 2020 (0d) |
| Oct 25, 2016 | MSON | ↑ Buy | 761,469 | $5.25 | $4.0M | Direct | Oct 26, 2016 (1d) |
| Jun 16, 2014 | MSON | ↑ Buy | 69,509 | $5.70 | $396K | Direct | Jun 18, 2014 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Stavros G. Vizirgianakis's insider trades
Stavros G. Vizirgianakis is a director at Xtant Medical Holdings (XTNT). Since Jun 16, 2014, Stavros has reported 4 open-market purchases worth $5.6M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (22 filings), option exercises (3 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XTNT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.